ABSTRACT

Compounds having the structural formula I

$$Z \xrightarrow{R^3} R^2 \xrightarrow{NH_2} N \xrightarrow{N-N-N} R$$

$$Z \xrightarrow{R^4} R^5$$

or a pharmaceutically acceptable salt thereof, wherein

5 R is

$$\xi = R^6 \qquad \xi = R^8$$
 or
$$\xi = R^7$$

R¹, R², R³, R⁴ and R⁵ are H, alkyl or alkoxyalkyl;

R⁶ is H, alkyl, hydroxyalkyl or -CH₂F;

 $\ensuremath{\mathsf{R}^{7}}$, $\ensuremath{\mathsf{R}^{8}}$ and $\ensuremath{\mathsf{R}^{9}}$ are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or $-\ensuremath{\mathsf{CF}_{3}}$; and

Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed.

Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

10